Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Asia Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Pharmaceutical and biotech stocks have taken a beating this year amid drug pricing news surrounding companies like Valeant and Mylan, and some investors may think it's crazy to buy a drug stock right now. Jim Cramer is willing to be called crazy.
In the past few weeks, Cramer's charitable trust has built a new pharmaceutical position in its portfolio for Bristol-Myers Squibb.
"The drug company I have referenced for years as the kind of high-quality secular growth business that is totally immunized against the slings and arrows of the Federal Reserve or a slowing economy," the "Mad Money" host said.
Bristol-Myers shares have fallen more than 26 percent in the past two months. On Aug. 5, the stock plunged 16 percent, wiping out $20 billion in value in a single session on news that its flagship oncology drug, Opdivo, failed to meet its primary endpoint in a clinical trial for advanced non-small cell lung cancer.
The news set back the company's most important drug and prompted analyst downgrades and estimate cuts.
"To me, at these levels, it just screams value, even as you might have to wait a while for this investment to pay off," Cramer said.
Opdivo is already available commercially and helps patients' immune systems' T-cells fight cancer more effectively. The drug has grown dramatically, as it generated nearly $1 billion in sales in 2015 and more than $1.5 billion for the first 6 months of 2016.
As soon as investors heard that the drug failed to meet its primary endpoint, Wall Street turned its back on the whole franchise, assuming that people would switch to a competitor like Merck's Keytruda.
However, Cramer said the drug did not meet goals because Bristol-Myers set the bar too high. When it designed the clinical trial, it included patients who expressed a specific protein by more than 5 percent — a very low level.
Why circle back to the stock now?
Cramer's charitable trust bought the stock because Opdivo estimates have now gone from too high to too low, now that most analysts have stripped the non-small lung cancer numbers from estimates.
Additionally, the company has another non-small cell lung cancer trial to pair Opdivo with another of its drugs. If that trial goes well, estimates will need to be raised.
"Let's not act like Bristol-Myers is some one-drug wonder biotech firm," Cramer said.
It has a host of drugs that treat a variety of diseases, and sports a robust drug pipeline even after taking Opdivo estimate cuts into account.
However, it is important for investors to keep in mind that Bristol-Myers is now a value investment that requires a long-term time horizon, Cramer said. It could take a year or two for the story to play out. Short term, it could be choppy and the stock could go lower. Cramer recommended pouncing on weakness, especially as there could be some heading into the election.
"In this negative environment for the drug industry, I think Bristol-Myers has finally come down to the point where it is simply too attractive to ignore as a long-term investment," Cramer said.